2022 WHO Biosimilar Guideline improves access, IGBA says
Under the revised 2022 WHO Biosimilars Guideline, IGBA says regulatory authorities can confidently revaluate biosimilar access requirements.
Vivian Frittelli Julie Mar Biosimilars Committee World Health Organization International Generic Biosimilar Medicines Association
Source: europeanpharmaceuticalreview.com